2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Buy
59
ABBV Quote, Financials, Valuation and Earnings
Last price:
$186.27
Seasonality move
:
1.68%
Day range:
$183.01 - $186.69
52-week range:
$156.20 - $218.66
Dividend yield:
3.43%
P/E ratio:
79.20x
P/S ratio:
5.75x
P/B ratio:
231.51x
Volume:
11.6M
Avg. volume:
7.5M
1-year change:
19.06%
Market cap:
$328.7B
Revenue:
$56.3B
EPS (TTM):
$2.35
Analysts' Opinion
-
Consensus RatingAbbVie has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 12 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $209.61, AbbVie has an estimated upside of 12.63% from its current price of $186.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $170.00 representing 8.66% downside risk from its current price of $186.11.
Fair Value
-
According to the consensus of 24 analysts, AbbVie has 12.63% upside to fair value with a price target of $209.61 per share.
ABBV vs. S&P 500
-
Over the past 5 trading days, AbbVie has overperformed the S&P 500 by 0.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AbbVie does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AbbVie has grown year-over-year revenues for 5 quarters straight. In the most recent quarter AbbVie reported revenues of $13.3B.
Earnings Growth
-
AbbVie earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AbbVie reported earnings per share of $0.72.
Enterprise value:
393.5B
EV / Invested capital:
5.51x
Price / LTM sales:
5.75x
EV / EBIT:
60.82x
EV / Revenue:
6.86x
PEG ratio (5yr expected):
--
EV / Free cash flow:
25.58x
Price / Operating cash flow:
21.44x
Enterprise value / EBITDA:
26.55x
Gross Profit (TTM):
$40.6B
Return On Assets:
2.97%
Net Income Margin (TTM):
7.31%
Return On Equity:
81.41%
Return On Invested Capital:
5.54%
Operating Margin:
29.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $56.7B | $54.4B | $57.4B | $12.3B | $13.3B | |
| Gross Profit | $39.4B | $33.9B | $40.6B | $8.2B | $9.3B | |
| Operating Income | $17B | $13.6B | $12.9B | $3B | $4B | |
| EBITDA | $19.8B | $18.5B | $14.8B | $4.5B | $4.4B | |
| Diluted EPS | $4.23 | $3.37 | $2.35 | $0.77 | $0.72 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.6B | $26.5B | $26.5B | $38.9B | $27.7B | |
| Total Assets | $150.5B | $143.2B | $134.5B | $148.9B | $136.2B | |
| Current Liabilities | $32B | $32.5B | $27.6B | $41.5B | $36.4B | |
| Total Liabilities | $136.8B | $126.9B | $121.2B | $140.8B | $134.7B | |
| Total Equity | $13.7B | $16.3B | $13.3B | $8B | $1.5B | |
| Total Debt | $85.5B | $73.5B | $62.1B | $74B | $69.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.2B | $22.7B | $16.4B | $4B | $1.6B | |
| Cash From Investing | $469M | -$11.1B | -$12B | -$9.6B | -$735M | |
| Cash From Financing | -$24B | -$211M | -$17.3B | $10.8B | -$1.3B | |
| Free Cash Flow | $23.5B | $21.9B | $15.4B | $3.8B | $1.4B | |
ABBV
Sector
Market Cap
$328.7B
$33.4M
Price % of 52-Week High
85.11%
45.25%
Dividend Yield
3.43%
0%
Shareholder Yield
2.8%
-0.66%
1-Year Price Total Return
19.07%
-40%
Beta (5-Year)
0.557
0.653
Dividend yield:
3.43%
Annualized payout:
$6.20
Payout ratio:
266.46%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$184.12
200-day SMA
Sell
Level
$188.96
Bollinger Bands (100)
Sell
Level
176.72 - 203.62
Chaikin Money Flow
Buy
Level
1.1B
20-day SMA
Buy
Level
$185.99
Relative Strength Index (RSI14)
Buy
Level
50.30
ADX Line
Sell
Level
21.47
Williams %R
Neutral
Level
-40.8189
50-day SMA
Sell
Level
$188.50
MACD (12, 26)
Sell
Level
-1.00
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
1.5B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8054)
Sell
CA Score
(Annual)
Level (-2.1465)
Buy
Beneish M-Score
(Annual)
Level (-3.0743)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.6133)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Stock Forecast FAQ
In the current month, ABBV has received 12 Buy ratings 12 Hold ratings, and 0 Sell ratings. The ABBV average analyst price target in the past 3 months is $209.61.
-
Where Will AbbVie Stock Be In 1 Year?
According to analysts, the consensus estimate is that AbbVie share price will rise to $209.61 per share over the next 12 months.
-
What Do Analysts Say About AbbVie?
Analysts are divided on their view about AbbVie share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AbbVie is a Sell and believe this share price will drop from its current level to $170.00.
-
What Is AbbVie's Price Target?
The price target for AbbVie over the next 1-year time period is forecast to be $209.61 according to 24 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is ABBV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AbbVie is a Leans Bullish. 12 of 24 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ABBV?
You can purchase shares of AbbVie via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AbbVie shares.
-
What Is The AbbVie Share Price Today?
AbbVie was last trading at $186.27 per share. This represents the most recent stock quote for AbbVie. Yesterday, AbbVie closed at $186.11 per share.
-
How To Buy AbbVie Stock Online?
In order to purchase AbbVie stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
